# A Real-Time, Bioluminescent Annexin V Assay for the Assessment of Apoptosis

Andrew Niles<sup>1</sup>, Kevin Kupcho<sup>1</sup>, Tracy Worzella<sup>1</sup>, John Shultz<sup>1</sup>, Wenhui Zhou<sup>2</sup>, Robin Hurst<sup>1</sup>, Jim Hartnett<sup>1</sup>, Thomas Machleidt<sup>1</sup>, Terry Riss<sup>1</sup>, Dan Lazar<sup>1</sup>, and James Cali<sup>1</sup> <sup>1</sup>Promega Corporation, 2800 Woods Hollow Rd, Madison, WI, 53711; <sup>2</sup>Promega Biosciences LLC, 277 Granada Dr, San Luis Obispo, CA 93401





equipped with an atmospheric control unit (ACU).

Panel A. Dose- and time-dependent increases in PS exposure due to apoptosis. Note kinetic divergence in apoptotic response vs. paclitaxel (Pane 7, Panel B). Panel B. Dose- and time-dependent losses in membrane integrity occur as a result of the progression of apoptosis.

### February 2017

**Panel A**. The bioluminescent annexin component produced a Z' of 0.79 after 24h of incubation with bortezomib. This Z' and fold signal change was largely maintained at 48h (data not shown). Panel B. The necrosis detection component produced a Z' of 0.59 at 24h and improved to 0.69 at 48h as cells progressed from apoptosis to secondary necrosis (data not shown).

### www.promega.com

## 7. Caspase Activity vs. Annexin Method



Exposure	Caspase EC <sub>50</sub>	Annexin EC <sub>50</sub>
15h	~ 6nM	~ 2nM
18h	~ 6nM	~ 2nM
24h	6.5nM	2.5nM
30h	6.6nM	2.7nM
48h	4.2nM	1.9nM



bortezomib (Pane 3). concordant.

# 8. Bioluminescence Imaging



60 120 180 240 300 360 420 480

time [min]





RealTime-Glo<sup>™</sup> Annexin V Apoptosis Assay reagent was added to adherent HeLa cells in CO<sub>2</sub>-independent medium and pre-incubated at 37°C for 2h. Staurosporine was added and luminescence collected over 8h (exposure 3 sec, 24 gain, 2x2 binning) using a modified Etaluma Lumascope (920 x 1200 pixels, 5.86 pixel size with Sony IMX174 CMOS Chip). Panels A-D. Luminescent cell numbers increase as apoptosis progresses. Panel E. An imaging algorithm characterized the relationship between individual apoptotic cell intensity and time.

The RealTime-Glo<sup>™</sup> Annexin V Apoptosis Assay:

9. Conclusions

Is fully homogeneous

4000-

2000-

<del>رى</del> 3000 -

- Utilizes the "Add-Mix-Measure" format
- No washes or sample preparation is required
- Can be employed in real-time for up to 48h
- Defines apoptosis induction kinetics and magnitude of response - Defines the kinetics of cell death as a result of the apoptotic program • Is scalable for high throughput formats
- Is suitably sensitive and robust for high density formats Produces excellent Z' values in 384-well format
- Produces data comparable to orthogonal, endpoint methods
- Excellent concordance with an endpoint caspase activity method Exhibits utility for bioluminescent imaging
- Links changes in morphology to the apoptotic phenotype
- Allows for analysis of apoptosis at the single cell level



**Bioluminescent Annexin [Real-Time]** 

Ā	Exposure Period	
	🔶 4 hrs	-0- 24 hrs
	- <b>0-</b> 7 hrs	- <b>0-</b> 27 hrs
	- <b>O-</b> 12 hrs	-0- 30 hrs
	-0- 15 hrs	- <b>0</b> - 36 hrs
	- <del>0-</del> 18 hrs	- <b>0</b> - 40 hrs
	- <b>O-</b> 21 hrs	- <b>O-</b> 48 hrs

HepG2 were dosed with paclitaxel. Note kinetic divergence in apoptotic induction kinetics vs.

Panel A. Caspase 3/7 activity data were collected in parallel plates at various time points using the Caspase-Glo™

3/7 Assay in endpoint format using seven separate plates. Panel B. Bioluminescent annexin data were collected in realtime using one plate with one addition. Panel C. Caspase activity and bioluminescence annexin  $EC_{50}$  values are

### 360 min